Portfolio company Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept) in IgA Nephropathy.
Vera Therapeutics is focused on transforming medicine in autoimmune diseases, particularly IgA nephropathy, through rigorous scientific research and patient-centered approaches
Vera Therapeutics is focused on transforming medicine in autoimmune diseases, particularly IgA nephropathy, through rigorous scientific research and patient-centered approaches.